Efficacy of Intense Pulsed Light in the Treatment of Recurrent Chalazia

Chalazion Clinical Trial

Official title:

Efficacy of Intense Pulsed Light in the Treatment of Recurrent Chalazia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05070611
• Other study ID #: 2021-0562
• Status: Recruiting
• Phase: N/A
• Start date: July 1, 2020
• Est. completion date: November 1, 2021

Study information

• Verified date: September 2021
• Source: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Contact: jin x ming
• Phone: 13989455778
• Email: 18344980413[@]qq.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the present study was to investigate the efficacy of intense pulse light and meibomian glands expression in cases of recurrent chalazion after surgery.

Description:

We hypothesized that IPL application on the skin adjacent to eyelids after chalazion surgery will result in better meibomian gland function and lower recurrence. To date, it has not been previously reported the outcomes of the use of this technology for the management of chalazions recurrence. The purpose of the present study was to investigate the efficacy of intense pulse light and meibomian glands expression in cases of recurrent chalazion after surgery.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 35
• Est. completion date: November 1, 2021
• Est. primary completion date: August 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 24 Years to 74 Years

Eligibility

Inclusion Criteria:

• All patients had chronic unilateral recurrent chalazia that failed to resolve after conservative treatment that included warm compresses and antibiotic and steroid ophthalmic ointments.

Exclusion Criteria:

• (1) any intraocular inflammation, ocular infection, allergy, ocular surgery, or ocular trauma in the past 6 months; (2) any eyelid diseases or structural abnormality; (3) any systematic diseases may lead to dry eye or MGD; (4) skin cancer or pigmented lesion in the treatment zone.

Related Conditions & MeSH terms

• Chalazion

Intervention

Device:
• IPL-MGX
One week after lesion incision, the E-Eye machine (E-SWIN company, France) IPL treatment was administered to the skin area below the lower eyelid.13 Before treatment, the eyes were protected with opaque goggles and ultrasound gel was applied on the patient's face from tragus to tragus including the nose to conduct the light.

Locations

Country	Name	City	State
China	Second Affiliated Hospital of Zhejiang University Hospital	Hangzhou

Sponsors (1)

Lead Sponsor	Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recurrence rate of chalazia	The recurrence rate of the recurrent chalazia	an average of 1 year
Secondary	NITBUT	non-invasive tear film breakup time	an average of 1 year
Secondary	meibomian expressibility and quality	The expressibility and quality score of the meibum	an average of 1 year
Secondary	TMH	tear meniscus height	an average of 1 year